What is clinically relevant? [Design Issues]

posted by nobody – 2018-04-05 12:04 (2579 d 23:54 ago) – Posting: # 18643
Views: 6,704

Hi Felix Austria!

Yeah, it's complicated, no question. PEG-ylated, non-PEG-ylated on top. Maybe this i.v. modified release formulations are as complicated as inhalative stuff...

But what I was asking for is the finding of the paper that depending on the T/R of the release rate the most appropriate/sensitive parameter should vary. Is that real or not? I can't make sense out of this (without reading the original paper, no 41.59 € worth for me...).

Let's say: if T releases faster than R, take AUCpart 0-24h. But if I switch T and R the same does not apply. Why that? I don't get it....

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
78 visitors (0 registered, 78 guests [including 4 identified bots]).
Forum time: 11:59 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5